6 research outputs found

    Constraints on the Detectability of Cosmic Topology from Observational Uncertainties

    Full text link
    Recent observational results suggest that our universe is nearly flat and well modelled within a Λ\LambdaCDM framework. The observed values of Ωm\Omega_{m} and ΩΛ\Omega_{\Lambda} inevitably involve uncertainties. Motivated by this, we make a systematic study of the necessary and sufficient conditions for undetectability as well as detectability (in principle) of cosmic topology (using pattern repetition) in presence of such uncertainties. We do this by developing two complementary methods to determine detectability for nearly flat universes. Using the first method we derive analytical conditions for undetectability for infinite redshift, the accuracy of which is then confirmed by the second method. Estimates based on WMAP data together with other measurements of the density parameters are used to illustrate both methods, which are shown to provide very similar results for high redshifts.Comment: 16 pages, 1 figure, LaTeX2

    Managing Product Variety: An Integrative Review and Research Directions

    No full text

    Ezetimibe added to statin therapy after acute coronary syndromes

    Get PDF
    BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known. METHODS: We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization ( 6530 days after randomization), or nonfatal stroke. The median follow-up was 6 years. RESULTS: The median time-weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy group (P<0.001). The Kaplan-Meier event rate for the primary end point at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in the simvastatin-monotherapy group (absolute risk difference, 2.0 percentage points; hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P = 0.016). Rates of pre-specified muscle, gallbladder, and hepatic adverse effects and cancer were similar in the two groups. CONCLUSIONS: When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit

    Individuality, phenotypic differentiation, dormancy and ‘persistence’ in culturable bacterial systems: commonalities shared by environmental, laboratory, and clinical microbiology

    No full text

    Involvement of inflammation in Alzheimer’s disease pathogenesis and therapeutic potential of anti-inflammatory agents

    No full text
    corecore